Pipeline Banner

Pipeline

Lenabasum

Preclinical
Phase 1
Phase 2
Phase 3
Commercial Rights
Phase 3 in progress
Corbus Pharmaceuticals Holdings, Inc.
Kaken Pharmaceutical Co., Ltd.
U.S., EU and Rest of WorldJapan
Phase 3 in progress
Corbus Pharmaceuticals Holdings, Inc.
Kaken Pharmaceutical Co., Ltd.
U.S., EU and Rest of WorldJapan

CRB-4001

NASH

Preclinical in progress
Corbus Pharmaceuticals Holdings, Inc.
Worldwide

Drug Discovery Library

  1. Health Advances, LLC Analysis
  2. “Scleroderma.” National Institute of Arthritis and Musculoskeletal and Skin Diseases, U.S. Department of Health and Human Services, 27 Aug. 2018, niams.nih.gov/health-topics/scleroderma/advanced#tab-risk.
  3. Solomon, J. J., et al. “Scleroderma Lung Disease.” European Respiratory Review, vol. 22, no. 127, 2013, pp. 6–19., doi:10.1183/09059180.00005512.
  4. National Institute of Arthritis and Musculoskeletal and Skin Diseases, U.S. Department of Health and Human Services, 27 Aug. 2018, www.niams.nih.gov/health-topics/scleroderma/advanced#tab-risk.
  5. Health Advances, LLC Analysis
  6. Tansley, Sarah L, et al. “Adult and Juvenile Dermatomyositis: Are the Distinct Clinical Features Explained by Our Current Understanding of Serological Subgroups and Pathogenic Mechanisms?” Arthritis Research & Therapy, vol. 15, no. 2, 8 Apr. 2013, p. 211., doi:10.1186/ar4198.
  7. Bernatsky, S, et al. “Estimating the Prevalence of Polymyositis and Dermatomyositis from Administrative Data: Age, Sex and Regional Differences.” Annals of the Rheumatic Diseases, vol. 68, no. 7, July 2009, pp. 1192–1196., doi:10.1136/ard.2008.093161.
  8. Health Advances, LLC Analysis
  9. “About Cystic Fibrosis.” CF Foundation, Cystic Fibrosis Foundation, cff.org/What-is-CF/About-Cystic-Fibrosis/.
  10. “Cystic Fibrosis-Related Diabetes.” CF Foundation, Cystic Fibrosis Foundation, https://www.cff.org/Life-With-CF/Daily-Life/Cystic-Fibrosis-Related-Diabetes/
  11. “Pulmonary Exacerbations Clinical Care Guidelines.” CF Foundation, Cystic Fibrosis Foundation, https://www.cff.org/Life-With-CF/Daily-Life/Cystic-Fibrosis-Related-Diabetes/
  12. Health Advances, LLC Analysis
  13. “Lupus.” Mayo Clinic, Mayo Clinic, 25 Oct. 2017, mayoclinic.org/diseases-conditions/lupus/symptoms-causes/syc-20365789.
  14. “Systemic Lupus Erythematosus (Lupus).” National Institute of Arthritis and Musculoskeletal and Skin Diseases, U.S. Department of Health and Human Services, 30 June 2016, niams.nih.gov/health-topics/lupus/advanced#tab-symptoms
  15. Merola, Jf, et al. “Clinical Manifestations and Survival among Adults with (SLE) According to Age at Diagnosis.” Lupus, vol. 23, no. 8, July 2014, pp. 778–784., doi:10.1177/0961203314526291.
  16. Mayo Clinic, Mayo Clinic, 25 Oct. 2017, www.mayoclinic.org/diseases-conditions/lupus/symptoms-causes/syc-20365789.
  17. “Systemic Lupus Erythematosus (Lupus).” National Institute of Arthritis and Musculoskeletal and Skin Diseases, U.S. Department of Health and Human Services, 30 June 2016, niams.nih.gov/health-topics/lupus/advanced#tab-symptoms
  18. Mayo Clinic, Mayo Clinic, 25 Oct. 2017, www.mayoclinic.org/diseases-conditions/lupus/symptoms-causes/syc-20365789.

Third-party websites are provided for convenience only. Corbus Pharmaceuticals Holdings, Inc. does not approve of, or endorse any of the content. Corbus Pharmaceuticals Holdings, Inc. does not maintain, control or monitor the content of third-party websites in any way.